Open AccessSystemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
Author(s) -
El Mehdi Tazi,
Ismail Essâdi,
Hind Mrabti,
Anass Touyar,
PR Hassan Errihani
Publication year - 2011
Publication title -
north american journal of medical sciences
Language(s) - English
Resource type - Journals
eISSN - 2250-1541
pISSN - 1947-2714
DOI - 10.4297/najms.2011.3167
Subject(s) - sorafenib , medicine , erlotinib , targeted therapy , tolerability , clinical trial , hepatocellular carcinoma , oncology , bevacizumab , cancer , chemotherapy , epidermal growth factor receptor , adverse effect
ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IS A MALIGNANCY OF GLOBAL IMPORTANCE: it is the sixth most common cancer and the third most common cause of cancer-related mortality worldwide. Despite decades of efforts by many investigators, systemic chemotherapy or hormone therapy has failed to demonstrate improved survival in patients with HCC.. Ongoing studies are evaluating the efficacy and tolerability of combining Sorafenib with erlotinib and other targeted agents or chemotherapy.